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Maurice Hall and Lezley-Anne Hanna 
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After completing this part of the module you will:  
• Appreciate why older adults should be considered as a special patient group with regard to 
medicines use 
• Understand the general principles that can be applied when prescribing or reviewing 
medicines use in older adults  
• Be able to identify problem/inappropriate medicines in older adults  
• Define specific ways that pharmacists can optimise the use of medicines older adults 
 
Demographic changes and an ageing population are key considerations for the Government and 
healthcare professionals when planning effective and appropriate healthcare. As previously outlined 
in the first part of the module, older adults have a higher prevalence of long-term conditions and 
undergo anatomical, physiological, psychological and sociological changes due to the ageing process. 
They are more likely to be prescribed medication and to take more medicines than younger adults 
which puts them at a higher risk of suffering adverse effects. Moreover, pharmacokinetic and 
pharmacodynamics changes caused by the ageing process further augments the risk of adverse effects 
from medicines.  Unfortunately, healthcare practitioners may not recognise that a patient’s symptoms 
could be iatrogenic and may instead prescribe further medicines (this is known as ‘incremental 
prescribing’ or the ‘prescribing cascade’) rather than conducting a thorough assessment to reach a 
differential diagnosis.  
 
Moreover, according to the National Institute for Health and Care Excellence (NICE) and a Cochrane 
systematic review, between a third and a half of all medicines prescribed for long‑ term conditions 
are not taken as recommended.1,2 Non‑ adherence can result in a lack of improvement or 
deterioration in health and has the potential to have significant economic implications. 
Non˗adherence is broadly divided into two main categories: unintentional and intentional. 
Unintentional non-adherence happens when the patient wants to follow the agreed treatment 
strategy but can’t do this due to reasons that are beyond their control (such as cognitive impairment 
and problems preventing them from physically using the treatment). Intentional non˗adherence 
occurs when the patient actively decides not to follow the treatment recommendations. According to 
NICE, addressing non‑ adherence should start with an exploration of patients' views of medicines and 
the reasons why they may not want or are unable to use them. Comprehensive information about 
adherence is provided by NICE and a Cochrane Systematic Review is available detailing interventions 
for enhancing medication adherence.1,2 
 
Various tools and criteria are available to help with prescribing and identifying potentially 
inappropriate medication use in older adults. Examples include the Beers Criteria (initially developed 
by Mark Beers),3 the Inappropriate Prescribing in the Elderly Tool (IPET),4 and the Screening Tool of 
Older Person's Prescriptions (STOPP) and Screening Tool to Alert doctors to Right Treatment (START).5 
The STOPP/START criteria have been used to review the medication profiles (acute and long-term 
conditions) of older patients living in the community-setting in Europe, Asia and the United States of 
America. A systematic review conducted by Hill-Taylor et al. (2013) concluded that while the 
STOPP/START criteria appear to be more sensitive than the Beers criteria (2002 version), limited 
evidence exists regarding the clinical and economic impact.6 Other useful and reputable resources 
relating to the healthcare of older adults are readily available and include: NICE, Age UK, Department 
of Health (including the 2001 National Service Framework for Older People), British Dental 
Association, British Heart Foundation, Diabetes UK, Macmillan Cancer Support and the Alzheimer’s 
Society. However, it must be remembered that older adults are seldom enrolled in clinical trials and 
therefore the results/evidence may not be applicable in practice. Indeed, many clinical trials and 
guidelines do not typically consider the use of medicines in the context of patients with multi-or co-
morbidities, making evidence-based clinical decision-making more challenging in this population.  
 
General tips:7,8 
• The dose needed may be smaller than an adult dose and dose titration in small increments 
may be required i.e. ‘start low and go slow’ 
• Directions should facilitate the safe and effective use of medicines. The dose and dosing 
frequency should be included on prescriptions (or discussed during an over-the-counter 
consultation) and imprecise instructions like 'as directed', ‘when required’ avoided 
• Ascertain whether the medicine is needed. Weigh up the benefits and risks and consider the 
evidence-base in the context of the older patient in tandem with patients’ opinions. 
Numerous minor ailments are self-limiting and over-the-counter medicines may lack robust 
evidence of effectiveness (such as cough medicines). Other problems could potentially be 
managed using non-pharmacological measures (such as insomnia). Patients should be aware 
of the current evidence-base to enable informed decisions to be made. Prior to adding in 
another medicine to a patient’s regimen to manage new symptoms, be mindful of iatrogenic 
causes 
• Try to avoid complicated dosing regimens. Use regimens with the lowest number of different 
agents and with once or twice daily dosing intervals 
• Many people will take medicines unnecessarily and therefore regular review is important. 
Consider if medicine(s) can be stopped, appreciating that palliative care applies to other 
chronic conditions, not just cancer 
• Ensure therapy is not needlessly duplicated and be mindful that drugs that increase the 
anticholinergic burden have sedative/hypnotic or hypotensive effects. Remember to consider 
the possibility of renal impairment and the implications this will have on medicine choice 
• For older adults with dysphagia (a common complication of a stroke) consider the formulation 
and/or giving advice about taking medicines with plenty of water whilst sitting upright 
(medicines that remain in the oromuscosa or oesophagus for a prolonged time may lead to 
ulceration). Non-viscous liquid medicines can increase coughing and aspiration risks (hence 
the rationale for thickening agents/fluids); it may be appropriate to investigate whether the 
tablet or capsule can be opened and sprinkled onto yoghurt, or swallowed whole when mixed 
with some food, prior to assuming a liquid formulation is always better/necessary 
 
Table 1 provides examples of medicines to be avoided or used with caution in older adults. This 
information should not be used in isolation of other relevant resources such as NICE Clinical 
Guidelines, the BNF or manufacturers’ information.  
 
Table 1 Examples of medicines to be avoided or used with caution in older adults 7,8 
 
Drugs to avoid/use with caution Rationale 
Amiodarone  Higher risk of adverse effects than other similar medicines 
Angiotensin Converting Enzyme 
(ACE) inhibitors or Angiotensin 
Receptor Blockers (ARBs) 
Aldosterone antagonists 
Risk of causing/exacerbating hyperkalaemia which can lead to 
arrhythmias but useful in diabetes with evidence of renal 
disease 
Anticholinergics (such as 
antimuscarinics and 1st generation 
antihistamines) 
Aluminium-containing antacids 
Verapamil 
Opiates 
Risk of causing/exacerbating constipation 
Anticholinergic medicines can also exacerbate glaucoma and 
cognitive impairment, and cause urinary retention, sedation. 
[High-strength opiates are necessary for moderate-severe pain 
where paracetamol or low strength opioids are ineffective] 
Anticoagulants and antiplatelets Care about long-term use. Risk of bleeding, particularly if used 
in combination (or with NSAIDs).  
If warfarin is to be prescribed, patients should understand why 
the drug is needed, dosing, the importance of monitoring and 
other safety issues. 
(Risk of bleeding applies to direct thrombin inhibitors or Factor 
Xa inhibitors; extent depends on creatinine clearance) 
Antidepressants Tricyclic antidepressants: similar efficacy to SSRIs but more 
likely to be discontinued due to side-effects; toxicity in 
overdosage is also an issue.  
Serotonergic agents may cause serotonin syndrome and 
agitation. 
Increased incidence of falls  
Hyponatraemia has been reported more frequently with SSRIs 
than with others (signs: drowsiness, confusion, or convulsions) 
Antidiabetic medicines Long-acting oral hypoglycaemics such as chlorpropamide and 
glibenclamide should be avoided due to the significant risk of 
hypoglycaemia. 
Risk of cardiac effects with thiazolidenediones 
Antipsychotics Some have anticholinergic effects, there is a risk of stroke and 
death with risperidone 
Increased incidence of falls 
Benzodiazepines Risk of prolonged sedation, confusion, increased incidence of 
falls. Risk of withdrawal syndrome if stopped suddenly 
Bisphosphonates Long-term use increases the risk of serious gastrointestinal 
disturbances including oesophagitis and ulceration, 
osteonecrosis of the jaw and atypical stress fractures 
Still may be required (for example, due to long-term systemic 
corticosteroid therapy) 
Colchicine Risk of toxicity (risk depends on creatinine clearance) 
Digoxin Increased risk of adverse effects, including toxicity (high 
strengths like 250 micrograms/day are likely to cause toxicity). 
Diuretics Loop diuretics may exacerbate incontinence; more effective 
and safer options are available. Thiazides may precipitate gout 
and exacerbate hypokalaemia, hyponatraemia, hypocalcaemia 
Diuretics are overused in older adults; when used to treat 
hypertension or cardiac failure, review regularly.  
Domperidone Risk of cardiac side effects 
Non-steroidal anti-inflammatory 
drugs (NSAIDs) 
Risk of cardiac side-effects, gastrointestinal problems including 
bleeding, and deterioration in renal function (combining 
NSAIDS and ACE inhibitors in older patients can be risky since 
their combined effect on renal cortical perfusion and function 
can result in significant renal impairment). 
Proton Pump Inhibitors (PPIs) Be mindful that PPIs may be a possible risk factor for C difficile 
infection (care in patients at high risk of C difficile).  
However, PPIs are beneficial for various indications including 
the prevention/treatment of medicine-induced peptic ulcers. 
Quinine sulphate Limited benefit of using long-term and risk of adverse effects 
(particularly with high doses) 
Stimulant Laxatives May exacerbate bowel dysfunction 
Theophylline Increased risk of adverse effects due to narrow therapeutic 
index/window 
 
Given that older adults are more likely to have chronic medical conditions, and hence have a 
corresponding greater need for medicines, they are frequently in contact with community 
pharmacists. Examples of community pharmacy services that are relevant for older adults, among 
others, are outlined below: 
 
Over-the-counter consultations 
With regard to counter-prescribing for older adults with over-the-counter (OTC) medicines, several of 
the medicines listed in Table 1 are also available over the counter and therefore the same caution 
should be exercised. Examples include:  
• sedating antihistamines found in cough and cold preparations and travel sickness tablets 
• antimuscarinics (hyoscine) present in irritable bowel syndrome and travel sickness 
preparations 
• opioids (such as codeine) used as cough suppressants and for analgesia 
• some NSAIDs that are available as topical and oral preparations (mainly ibuprofen since 
naproxen is indicated for primary dysmenorrhoea which would not be applicable to older 
adults). Oral diclofenac was reclassified to prescription-only status in 2015 due to cardiac risks 
• aspirin and stimulant laxatives such as senna and bisacodyl 
 
Moreover, several OTC products are not licensed for use in older adults. For example, Imigran 
Recovery is licensed for use in adults aged 18-65 years only,9 Canesten vaginal thrush products are for 
use in people aged 16 to 60 years (medical advice should be sought if over 60 years),9 Flomax Relief 
MR is licensed for men aged 45 to 75 years.9 Furthermore, OTC proton-pump inhibitors and ranitidine 
usually include a warning to seek medical advice if the person is middle-aged or older with new or 
recently changed symptoms.9  The Electronic Medicines Compendium is a key resource for 
manufacturers information (Summary of Product Characteristics and Patient Information Leaflet). 9  
 
Dispensing prescriptions and providing counselling 
Many opportunities exist for community pharmacists to engage with older adults at the point of 
dispensing. Questioning enables problems, such as adverse drug reactions, to be quickly identified and 
appropriate actions taken. It also allows pharmacists to gauge whether the formulation, packaging 
and labelling of the medicine is appropriate for the patient. As some people will not be able to get to 
the pharmacy, it is important to ensure that carers or others who are collecting or delivering medicines 
are aware of any important counselling points. 
 
Repeat dispensing 
Repeat dispensing, which allows patients to obtain supplies of their regular medicines over a defined 
period of time without the need to contact their surgery, is particularly useful for older adults. As 
previously mentioned, many older adults have one or more chronic medical conditions that are likely 
to be stable for the length of the repeatable prescription. Given the potential benefits (reduced waste, 
cost, risk, and more efficient use of time and skills) the uptake of the service should be promoted. 
Processes should be implemented in GP Practices to identify patients and pharmacists should also give 
advice to suitable patients about the benefits of such a service. 
 
Reviewing medication  
Readers are recommended to familiarise themselves with the NICE Medicines Optimisation pathway10 
where guidance on how to conduct a structured medication review is provided.  Information on the 
specific ‘Medicines Use Review (MUR)’ community pharmacy service is available: 
• England - Pharmaceutical Services Negotiating Committee (PSNC) 
[http://psnc.org.uk/services-commissioning/advanced-services/murs/] 
• Wales - Community Pharmacy Wales [http://www.cpwales.org.uk/Contractors-
Area/Pharmacy-Contact---Services/Advanced-Services/MUR-s.aspx] 
• Northern Ireland - Business Service Organisation (BSO) 
[http://www.hscbusiness.hscni.net/services/2427.htm] 
• Scotland’s ‘Chronic Medication Service’ (rather than the MUR service)  – NHS Scotland 
http://www.communitypharmacy.scot.nhs.uk/core_services/cms.html 
 
Older adults continue to be a growing and important demographic, who have much to benefit from 
pharmacist-led interventions and expertise. Within an NHS with limited resources, it is important that 
safe and effective drug use exists in all age-groups, but especially among those who are at greatest 
need of pharmaceutical care. 
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